Improved high-performance liquid chromatographic assay for the determination of procainamide and its N-acetylated metabolite in plasma: application to a single-dose pharmacokinetic study.
An improved high-performance liquid chromatographic assay for the determination of procainamide and N-acetylprocainamide (NAPA) at concentrations observed up to 32 h after a single oral dose administration of procainamide to human subjects is reported. Following liquid-liquid extraction of plasma samples, procainamide, NAPA, and the internal standard (N-propionylprocainamide) are separated on a reversed-phase C8 column with retention times of 4.0, 6.7, and 13.2 min, respectively. The ultraviolet detection limit (wavelength, 280 nm) of procainamide and NAPA is 2 ng/mL (signal-to-noise ratio, 3:1), and the quantitation limit is 4 ng/mL (signal-to-noise ratio, 5:1). Intra- and interday coefficients of variation are less than 8% in the range of 20-500 ng/mL.
Lessard
E
E
Faculty of Pharmacy, Laval University and Quebec Heart Institute, Laval Hospital, Sainte-Foy, Canada.
Fortin
A
A
Coquet
A
A
Bélanger
P M
PM
Hamelin
B A
BA
Turgeon
J
J
D000120:Acecainide / Q000097:blood*; D000107:Acetylation; D000889:Anti-Arrhythmia Agents / Q000097:blood* / Q000493:pharmacokinetics; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007202:Indicators and Reagents; D011342:Procainamide / Q000097:blood* / Q000493:pharmacokinetics; D012044:Regression Analysis; D013056:Spectrophotometry, Ultraviolet
D000889:Anti-Arrhythmia Agents; D007202:Indicators and Reagents; D000120:Acecainide; D011342:Procainamide